| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a chemical linker, Tr-PEG4 does not have a specific biological target. Its primary role is as a linker in ADCs. The antibody guides the ADC to cancer cells, and once bound to the antigen, the ADC is internalized, and the cytotoxic drug is released to kill the cancer cell. The exact biochemical pathways affected depend on the specific antibody and cytotoxic drug used in the ADC.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
Tr-PEG4 itself does not exhibit direct biological activity. Its activity is dependent on the final conjugated ADC molecule. The linker's properties, such as length and hydrophilicity, can influence the pharmacokinetics and efficacy of the final construct. The PEG linker can enhance the solubility and stability of the ADC. |
| ln Vivo |
Tr-PEG4 is not a therapeutic agent and does not have direct in vivo activity. Its function is as a chemical intermediate in the synthesis of active pharmaceutical ingredients. The in vivo properties of the final ADC are determined by the entire molecule, including the antibody, payload, and linker. ADCs are designed to have a long circulation time to maximize the chance of reaching target cancer cells.
|
| Enzyme Assay |
Non-cell based assays are not applicable for Tr-PEG4 as it is not a direct enzyme inhibitor or receptor ligand. Its identity and purity are confirmed using analytical techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry. Its utility as a linker is assessed in chemical synthesis, where the successful formation of the desired conjugate is verified.
|
| Cell Assay |
Cell-based assays are not applicable for Tr-PEG4, as it is not a biologically active compound. Its use is strictly limited to chemical synthesis. It is not tested in cell-based assays for direct biological activity. The biological activity is evaluated on the final ADC molecule that incorporates this linker.
|
| Animal Protocol |
In vivo animal experiments are not applicable for Tr-PEG4 as it is not a therapeutic agent. It is not administered to animals for pharmacological or toxicological studies. Its use is limited to the synthesis of other compounds. The pharmacokinetics of the final ADC can be studied in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties are not applicable for Tr-PEG4 as a standalone drug substance. However, as part of an ADC, a PEG linker can enhance the solubility and stability of the conjugate, potentially improving its PK properties. The compound has a molecular weight of 392.5 g/mol and a molecular formula of C25H28O4. It should be stored at -20°C in a dry, dark place.
|
| Toxicity/Toxicokinetics |
Toxicology data are not relevant for Tr-PEG4 as a standalone drug substance, as it is not administered to patients. As a chemical reagent, it should be handled with appropriate safety precautions. It may be an irritant if ingested, inhaled, or absorbed through the skin.
|
| References | |
| Additional Infomation |
Other information: Tr-PEG4 is a PEG linker used in the synthesis of antibody-drug conjugates (ADCs). It is also known as 2-[2-(2-trityloxyethoxy)ethoxy]ethanol. The compound is available from chemical suppliers for research purposes. Its CAS number is 133699-09-9.
|
| Molecular Formula |
C25H28O4
|
|---|---|
| Molecular Weight |
392.48700
|
| Exact Mass |
392.199
|
| CAS # |
133699-09-9
|
| PubChem CID |
11825346
|
| Appearance |
Colorless to light yellow viscous liquid
|
| Density |
1.126±0.06 g/cm3(Predicted)
|
| Boiling Point |
521.8±45.0 °C(Predicted)
|
| LogP |
4.02
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
29
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCOCCOCCO
|
| InChi Key |
CKYIMQGYUMGSEO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H28O4/c26-16-17-27-18-19-28-20-21-29-25(22-10-4-1-5-11-22,23-12-6-2-7-13-23)24-14-8-3-9-15-24/h1-15,26H,16-21H2
|
| Chemical Name |
2-[2-(2-trityloxyethoxy)ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5478 mL | 12.7392 mL | 25.4784 mL | |
| 5 mM | 0.5096 mL | 2.5478 mL | 5.0957 mL | |
| 10 mM | 0.2548 mL | 1.2739 mL | 2.5478 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
